Literature DB >> 21342216

Introduction to haemostasis from a pharmacodynamic perspective.

Cornelis Kluft1, Jacobus Burggraaf.   

Abstract

Biochemical characterization of the haemostatic system has advanced significantly in the past decades. Sub-systems, such as coagulation, fibrinolysis, blood cells and platelets and the vessel wall have been studied by specialists, mostly separately and independently. The time has come to integrate the approaches, and, in particular, to develop tests to document the state of the whole system and to have available adequate pharmacodynamic tests to evaluate treatments. Many examples are available to show that traditional general methods of clotting and lysis do not provide the information that is desired. The present tendency is to use specific methods for specific factors or effects which are very limited in pharmacological information. There is also increasing awareness of the occurrence of rather broad interindividual variability in the haemostatic system. This suggests that individually tailored treatments are required. This is the more relevant since haemostasis is a balance and treatment should be positioned between efficacy and safety. The conclusion is reached that there is a need for integrated or global methods or sets of methods that reflect the complexity and individual status appropriately and allow the practitioner to judge the effects of interventions and their individual aspects.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342216      PMCID: PMC3195731          DOI: 10.1111/j.1365-2125.2011.03946.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  65 in total

1.  A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor.

Authors:  K Strandberg; M Kjellberg; R Knebel; H Lilja; J Stenflo
Journal:  Thromb Haemost       Date:  2001-08       Impact factor: 5.249

2.  Measurement of collagen- and serotonin-induced platelet aggregation in whole blood.

Authors:  Matthijs Moerland; Michiel J Kemme; Monique van der Linden; Jacobus Burggraaf
Journal:  Expert Rev Clin Pharmacol       Date:  2010-03       Impact factor: 5.045

Review 3.  Mathematical modeling and computer simulation in blood coagulation.

Authors:  Fazoil I Ataullakhanov; Mikhail A Panteleev
Journal:  Pathophysiol Haemost Thromb       Date:  2005

Review 4.  Laboratory monitoring of anticoagulation: where do we stand?

Authors:  Armando Tripodi; Antonius van den Besselaar
Journal:  Semin Thromb Hemost       Date:  2009-03-23       Impact factor: 4.180

Review 5.  Blood coagulation factors as inflammatory mediators.

Authors:  Saskia H H F Schoenmakers; Pieter H Reitsma; C Arnold Spek
Journal:  Blood Cells Mol Dis       Date:  2005 Jan-Feb       Impact factor: 3.039

Review 6.  Elevated clotting factor levels and venous thrombosis.

Authors:  Rogier M Bertina
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Sep-2004 Dec

7.  Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.

Authors:  Guy Young; Karyn E Yonekawa; Peggy A Nakagawa; Rachelle C Blain; Amy E Lovejoy; Diane J Nugent
Journal:  Blood Coagul Fibrinolysis       Date:  2007-03       Impact factor: 1.276

Review 8.  Cellular microparticles: new players in the field of vascular disease?

Authors:  M Diamant; M E Tushuizen; A Sturk; R Nieuwland
Journal:  Eur J Clin Invest       Date:  2004-06       Impact factor: 4.686

Review 9.  Fibrin and fibrinolysis in infection and host defense.

Authors:  J L Degen; T H Bugge; J D Goguen
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

10.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

View more
  2 in total

Review 1.  Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

Authors:  Steen Husted; Freek W A Verheugt; Willemijn J Comuth
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

2.  Flavonoid Preparations from Taraxacum officinale L. Fruits-A Phytochemical, Antioxidant and Hemostasis Studies.

Authors:  Bernadetta Lis; Dariusz Jedrejek; Joanna Rywaniak; Agata Soluch; Anna Stochmal; Beata Olas
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.